Cannabis Law Report

JUNE 29, 2021

We look forward to his expertise as we expand our mental health analytical platform and enter clinical trials. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. ramps up to begin clinical trials by adding esteemed medical professional to its medical advisory board.

Clinical Trials 105

Clinical Trials Research and Development Data Patients 105

Puff Puff Post

MARCH 10, 2020

InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com. Visit [link].

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

DECEMBER 14, 2021

IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The trial was conducted as a multiple ascending dose (MAD) study.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

NORML

APRIL 30, 2020

.” The CDC’s interest in alternative methods of chronic pain management may be of particular significance to many medical cannabis patients. According to state-registry records, “Chronic pain is currently and historically the most common qualifying condition reported by medical cannabis patients (67.5

Chronic Pain 341

Chronic Pain Clinical Trials Data Patients 341

CannaMD

JUNE 2, 2021

As the study authors stated: The wider availability [of marijuana] means Parkinson’s patients have more of an opportunity now to experiment with it as a potential means of controlling their symptoms. However, little is known about these patients’ thoughts and experiences related to cannabis, or its perceived effect on the disease’s symptoms.

Patients 105

Patients Clinical Trials Treatment Research and Development 105

The Cannigma

MARCH 18, 2021

Published in Nature Partner Journals and sponsored by the Parkinson’s Foundation, the study found that nearly 25% of Parkinson’s patients had used cannabis in the past six months, but that one in four of that group did not know what type or form of cannabis they used, and nearly half did not know their dosage. Of the 43.9% Of the 43.9%

Patients 138

Patients Clinical Trials Treatment Cannabis 138

Veriheal

MAY 12, 2021

In light of such, and the fact that cancer is a common qualifying condition for cannabis, this research team took to expanding the available basic information on cannabis in the cancer population in order to provide clinical trial designers with better information needed for planned studies.

Patients 98

Patients Consumption Clinical Trials Education 98

Puff Puff Post

MARCH 10, 2020

InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com. Visit [link].

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Veriheal

MAY 26, 2022

Patients around the world are in need of natural, alternative medical solutions, and Realm of Caring (RoC) is on a mission to serve them. RoC also works to increase patients’ access to medical cannabis by helping U.S. To date, Veriheal’s global team has helped hundreds of thousands of patients gain access to medical cannabis.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

NORML

JANUARY 17, 2019

A bipartisan coalition of House lawmakers has introduced The Medical Cannabis Research Act of 2019 ( HR 601 ), to facilitate federally-approved clinical trials involving cannabis. Click here to send a message to your Representative and urge them to support the measure. .

Clinical Trials 230

Clinical Trials Legislation DEA Strains 230

Cannabis Law Report

OCTOBER 6, 2021

(NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally. or follow @floragrowthcorp on social for more information. Visit www.floragrowth.ca

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

The Cannigma

FEBRUARY 2, 2021

In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition. Patients can also access CBD products without a prescription through local pharmacies.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Veriheal

AUGUST 28, 2023

Recent studies have shown that psilocybin may effectively treat patients with obsessive-compulsive disorder (OCD). And it further reinforces the need to carry out clinical trials to determine the safety and efficiency of using psilocybin to treat OCD. In some cases, these patients are prone to depression and suicide.

Treatment 78

Treatment Clinical Trials Therapy Research and Development 78

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? In fact, from pediatricians to geriatricians, I cannot think of any medical practitioner that does not need to be well informed about the endocannabinoid system and cannabis-based therapeutics. million medical marijuana patients nationwide.

Patients 98

Patients Education Marijuana Therapy 98

SpeedWeed

MARCH 30, 2021

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. However, with the database not yet available to the nation’s private clinics there are concerns over the quality and volume of data it will garner.

Data 52

Data Patients Clinical Trials Business 52

Otherside Farms

JANUARY 25, 2019

A medical marijuana patient in Los Angeles with inoperable liver cancer has been removed from Cedars-Sinai Medical Center’s transplant list after testing positive for marijuana. Sixty-three-year-old medical marijuana patient Norman B. The letter also urges Cedars-Sinai to change its transplant eligibility policy. Dr. Steven D.

Patients 76

Patients Clinical Trials Marijuana Policy 76

MMJ Recs

JUNE 15, 2022

The best pain management physicians collaborate with the patient to develop a treatment regimen that works best for them as an individual. They offer top-rated doctors and pain relief specialists that work with each patient to develop a treatment plan tailored to their specific needs. Unique Pain Medicine.

Patients 52

Patients Treatment Clinical Trials Therapy 52

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Canna Care Docs

OCTOBER 3, 2023

On top of overwhelming struggles or feelings, patients who have been diagnosed with a terminal illness can face a broad range of both physical and psychological effects. Some patients diagnosed with a terminal illness may begin to feel depressed or physically and mentally lethargic from the effects and symptoms of their disease.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Cannabis Law Report

AUGUST 7, 2021

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. The right candidate will have a passion for clinical research in novel therapeutics and a proven track record of regulatory affairs experience. Key Responsibilities.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105

Cannabis Law Report

JUNE 21, 2021

RYAH publishes monthly reports discussing various topics arising from their analysis of the reams of data in its proprietary RYAH Cloud database, offering a glimpse of how the information can be used. The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain. Advantages of Data, Macro, and Micro.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

JUNE 8, 2021

This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. For more information, visit www.silopharma.com. Safe Harbor and Forward-Looking Statements.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results. reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

MMJ Recs

APRIL 1, 2024

Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders. Exploring CBD for Medical Use As interest in CBD grows, researchers are continuously exploring its potential applications in the medical field.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Veriheal

FEBRUARY 9, 2023

A fascinating new clinical trial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures. This will offer professionals worldwide a chance to gain insight into this research, equipping them with valuable information they can apply in their own contexts.

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Veriheal

MAY 3, 2022

Clinical Trial Sample Size. The trial was conducted with just 186 participants, which is far too small of a sample size to provide findings generalizable to the larger population. Missing Information. While lengthy, there is a surprising amount of missing information in the study.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Cannabis Law Report

NOVEMBER 23, 2021

London, UK – 23 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office. Availability of other information about COMPASS Pathways.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

AUGUST 10, 2022

The lead investigators are Jacobo Mintzer , MD, MBA, Brigid Reynolds , ANP-BC, and the Alzheimer’s Clinical Trial Consortium (ACTC).The This trial benefits from passionate lead investigators, a world-renowned sponsor institution and funding from the US National Institute of Health. MediPharm Labs Corp.

Clinical Trials 52

Clinical Trials Medicine Pharmaceutical THC 52

Cannabis Law Report

AUGUST 12, 2021

11, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2021 and gave an update on recent progress across its business. LONDON, Aug. Business highlights.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

AUGUST 19, 2019

There have been more than 7,500 approvals for medicinal cannabis in Australia since legalisation in 2016 – so why don’t we know if it is helping patients? Access to medicinal cannabis for patients was legalised in Australia in 2016, allowing doctors to request permission to prescribe from the Australian government.

Medicine 45

Medicine Patients Clinical Trials Access 45

Cannabis Law Report

JUNE 30, 2021

In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials. Despite the high prevalence of these disorders, few patients are accurately screened and diagnosed. Mental Health Challenges.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

MMJ Recs

NOVEMBER 30, 2023

While traditional treatments like antiepileptic drugs exist, they may not always provide adequate relief for all patients. While research is ongoing, some patients have reported remarkable improvements in their seizure control when using MMJ. Some patients have shared their experiences with using MMJ to manage their condition.

Epilepsy 105

Epilepsy Treatment Patients Strains 105

Cannabis Law Report

JULY 7, 2021

The country, which Tilray said has an estimated medical marijuana demand of more than 100,000 patients, legalized the drug for medical use in 2017 but has since relied on importing it. What they’re asking is … for information,” she said, like how the products are used, how patients can be instructed, and what dosage is. “We

Clinical Trials 105

Clinical Trials Education Data Pharmaceutical 105

Cannabis Law Report

OCTOBER 2, 2021

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. The right candidate will have a passion for clinical research in novel therapeutics and a proven track record of regulatory affairs experience. Key Responsibilities.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. Highlights from the presentation include: Declining PSA levels in treated patients. Declining circulating tumor cell (CTC) count in treated patients. Phase 2 trial underway. Abstract Number: 5015.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52